Pastre, Jean
Barnett, Scott
Ksovreli, Inga
Taylor, Jeannie
Brown, A. Whitney
Shlobin, Oksana A.
Ahmad, Kareem
Khangoora, Vikramjit
Aryal, Shambhu
King, Christopher S.
Nathan, Steven D.
Funding for this research was provided by:
Assistance publique-Hôpitaux de Paris
Philippe Foundation
Article History
Received: 24 August 2020
Accepted: 10 December 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: Local IRB committee (Inova Fairfax Hospital) approval was obtained. The need for informed consent was waived because of the retrospective nature of the study.
: Not applicable.
: SDN is a consultant for Actelion, Bellerophon, Roche-Genentech, Boerhinger-Ingelheim, Pliant, Merck, United Therapeutics and Bayer Pharmaceuticals. He is also on the Speakers’ Bureau for Roche-Genentech, Boerhinger-Ingelheim, and Bayer Pharmaceuticals. AWB has served on an advisory board for Promedior, Theravance, and Genentech, and serves on the Speakers’ Bureau for Genentech. OAS has served as a consultant and serves on the Speakers’ Bureau for Lung Rx/United Therapeutics, Actelion and Bayer. JP has served as a consultant for Boerhinger-Ingelheim. CSK has served on an advisory board for Boerhinher-Ingelheim, Actelion and United Therapeutics. He is on the speakers’ bureau for Genentech. He has served as a consultant for the France Foundation.